2023 Q2 Form 10-Q Financial Statement

#000141057823000987 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.690M $2.200M $1.455M
YoY Change 164.5% 51.2% 2.54%
% of Gross Profit
Research & Development $3.133M $2.977M $2.597M
YoY Change -10.1% 14.63% 132.29%
% of Gross Profit
Depreciation & Amortization $30.00K $32.00K $18.00K
YoY Change 66.67% 77.78% -45.45%
% of Gross Profit
Operating Expenses $5.820M $5.178M $4.252M
YoY Change 16.75% 21.78% 67.6%
Operating Profit -$5.820M -$5.178M -$4.252M
YoY Change 16.75% 21.78% 67.6%
Interest Expense $380.0K $370.0K -$21.00K
YoY Change 2135.29% -1861.9%
% of Operating Profit
Other Income/Expense, Net $377.0K $370.0K -$21.00K
YoY Change 2117.65% -1861.9%
Pretax Income -$5.443M -$4.808M -$4.273M
YoY Change 9.56% 12.52% 68.43%
Income Tax -$359.0K -$330.0K $0.00
% Of Pretax Income
Net Earnings -$5.100M -$4.478M -$4.273M
YoY Change 2.66% 4.8% 68.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34 -$0.30 -$0.03
Diluted Earnings Per Share -$0.34 -$0.30 -$0.03
COMMON SHARES
Basic Shares Outstanding 15.12M 15.12M 138.2M
Diluted Shares Outstanding 15.17M 15.12M 138.2M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.25M $36.08M $56.69M
YoY Change -34.47% -36.36% -26.27%
Cash & Equivalents $34.20M $36.08M $56.69M
Short-Term Investments
Other Short-Term Assets $3.430M $3.990M $1.142M
YoY Change 46.33% 249.39% -34.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables $144.0K $4.000K $127.0K
Total Short-Term Assets $37.97M $40.30M $59.56M
YoY Change -30.83% -32.33% -24.26%
LONG-TERM ASSETS
Property, Plant & Equipment $301.0K $324.0K $302.0K
YoY Change 5.61% 7.28% -23.54%
Goodwill $5.621M $5.617M $5.809M
YoY Change 8.41% -3.31%
Intangibles $19.48M $19.47M $21.87M
YoY Change -5.25% -10.97%
Long-Term Investments
YoY Change
Other Assets $120.0K $120.0K $126.0K
YoY Change 0.84% -4.76% 447.83%
Total Long-Term Assets $27.48M $27.59M $29.44M
YoY Change 0.15% -6.31% 6944.02%
TOTAL ASSETS
Total Short-Term Assets $37.97M $40.30M $59.56M
Total Long-Term Assets $27.48M $27.59M $29.44M
Total Assets $65.45M $67.89M $89.00M
YoY Change -20.51% -23.72% 12.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $741.0K $480.0K $1.354M
YoY Change -26.12% -64.55% 118.04%
Accrued Expenses $1.826M $2.076M $1.535M
YoY Change -8.1% 35.24% 2.27%
Deferred Revenue
YoY Change
Short-Term Debt $67.00K $66.00K $68.00K
YoY Change 19.64% -2.94%
Long-Term Debt Due $70.00K $70.00K $68.00K
YoY Change 25.0% 2.94%
Total Short-Term Liabilities $9.134M $8.619M $10.98M
YoY Change -31.14% -21.47% 417.25%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K $160.0K $229.0K
YoY Change -30.56% -30.13%
Other Long-Term Liabilities $7.460M $7.210M $6.039M
YoY Change 103.16% 19.39% 5491.67%
Total Long-Term Liabilities $7.610M $7.370M $6.268M
YoY Change 95.73% 17.58% 5703.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.134M $8.619M $10.98M
Total Long-Term Liabilities $7.610M $7.370M $6.268M
Total Liabilities $17.70M $17.30M $20.97M
YoY Change -14.33% -17.51% -3955.15%
SHAREHOLDERS EQUITY
Retained Earnings -$300.5M -$295.4M -$275.6M
YoY Change 7.13% 7.22%
Common Stock $346.2M $343.9M $343.4M
YoY Change 0.78% 0.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K $288.0K
YoY Change
Treasury Stock Shares $720.2K
Shareholders Equity $47.75M $50.59M $68.03M
YoY Change
Total Liabilities & Shareholders Equity $65.45M $67.89M $89.00M
YoY Change -20.51% -23.72% 12.58%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$5.100M -$4.478M -$4.273M
YoY Change 2.66% 4.8% 68.49%
Depreciation, Depletion And Amortization $30.00K $32.00K $18.00K
YoY Change 66.67% 77.78% -45.45%
Cash From Operating Activities -$3.890M -$5.610M -$4.902M
YoY Change -10.7% 14.44% 47.3%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $8.000K $0.00
YoY Change -171.43% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$4.280M
YoY Change -100.0%
Cash From Investing Activities -$10.00K -$8.000K -$4.280M
YoY Change -28.57% -99.81% 30471.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net $55.00K $1.376M
YoY Change -96.0%
Cash From Financing Activities 2.140M -55.00K -1.376M
YoY Change -96.0% -101.86%
NET CHANGE
Cash From Operating Activities -3.890M -5.610M -4.902M
Cash From Investing Activities -10.00K -8.000K -4.280M
Cash From Financing Activities 2.140M -55.00K -1.376M
Net Change In Cash -1.760M -5.708M -10.53M
YoY Change -59.73% -45.79% -114.9%
FREE CASH FLOW
Cash From Operating Activities -$3.890M -$5.610M -$4.902M
Capital Expenditures $10.00K $8.000K $0.00
Free Cash Flow -$3.900M -$5.618M -$4.902M
YoY Change -10.18% 14.61% 46.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 tovx Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
CY2023Q1 tovx Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-12584
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2023Q1 dei Entity Address Country
EntityAddressCountry
MD
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2023Q1 dei City Area Code
CityAreaCode
301
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
417-4364
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
TOVX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15124061
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36076000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41786000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4223000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
40299000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
45520000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
324000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
99000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2054000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1199000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19469000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19150000
CY2023Q1 us-gaap Goodwill
Goodwill
5617000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
CY2023Q1 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2022Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2023Q1 us-gaap Assets
Assets
67886000
CY2022Q4 us-gaap Assets
Assets
71861000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
480000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
915000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2076000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1496000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
649000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4911000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
2973000
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
66000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
57000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
437000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8619000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7060000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5408000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7211000
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
160000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
221000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1311000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1618000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1802000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1187000
CY2023Q1 us-gaap Liabilities
Liabilities
17300000
CY2022Q4 us-gaap Liabilities
Liabilities
17297000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844294
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15124061
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844294
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15124061
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343876000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343750000
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
720233
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
720233
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-305000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-679000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295447000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290969000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47852000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67886000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
126000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71861000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2201000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1655000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2977000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2597000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5178000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
4252000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5178000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4252000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-23000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
364000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4808000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4273000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-330000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4478000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4273000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15124061
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15124061
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13820144
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13820144
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
374000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
181000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4104000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4092000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
126000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-374000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47852000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
112000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-181000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
112000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-330000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
135000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2023Q1 tovx Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
82000
CY2022Q1 tovx Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
45000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
447000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-390000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-440000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
568000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-513000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-758000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-645000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-100000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-49000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5610000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4902000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2023Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
CY2022Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
CY2023Q1 tovx Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
0
CY2022Q1 tovx Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4280000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
55000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-55000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1376000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-35000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5708000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10530000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41884000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36176000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56795000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36076000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56692000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36176000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56795000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 tovx Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
0
CY2022Q1 tovx Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
12158000
CY2023Q1 tovx Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
0
CY2022Q1 tovx Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
CY2023Q1 tovx Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
0
CY2022Q1 tovx Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q1 tovx Number Of Intangible Assets Generated As Result Of Acquisition
NumberOfIntangibleAssetsGeneratedAsResultOfAcquisition
2
CY2023Q1 tovx Long Lived Assets For Assets Property Equipment And Right Of Use Assets.
LongLivedAssetsForAssetsPropertyEquipmentAndRightOfUseAssets.
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets include property, equipment and right-of-use assets. Management reviews the Company’s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. No impairment charges were recorded during the three months ended March 31, 2023 and 2022.</p>
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q4 us-gaap Goodwill
Goodwill
0
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
6757000
CY2022 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1061000
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
171000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
CY2023Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-92000
CY2023Q1 us-gaap Goodwill
Goodwill
5617000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
135000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
0
CY2023Q1 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
838000
CY2022Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
807000
CY2023Q1 tovx Accrued Vendor Payments
AccruedVendorPayments
375000
CY2023Q1 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2474000
CY2022Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2293000
CY2023Q1 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
879000
CY2022Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
418000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
440000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
637000
CY2023Q1 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
229000
CY2022Q4 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
144000
CY2023Q1 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
197000
CY2022Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
155000
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4223000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1221000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1210000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
897000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
865000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
324000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q1 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
863000
CY2022Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
197000
CY2022Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
492000
CY2023Q1 tovx Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
2076000
CY2022Q4 tovx Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1496000
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
325000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1216000
CY2023Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
142000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
100000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
182000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
87000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
649000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
841000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
900000
CY2020Q4 tovx Over Allotment Option Period
OverAllotmentOptionPeriod
P45D
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1165575
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
CY2023Q1 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price Decrease
PreferredStockConvertibleConversionPriceDecrease
1.22
CY2022 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y9M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022 tovx Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0
CY2022 tovx Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
71
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
182
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y9M10D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2023Q1 tovx Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0
CY2023Q1 tovx Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y6M10D
CY2018Q1 tovx Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
714
CY2018Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4500000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4300000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2022Q3 tovx Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
20000
CY2022Q3 tovx Votes Relating To Preferred Stock
VotesRelatingToPreferredStock
1549295
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
66000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
160000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
57000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
221000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
61000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
64000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
52000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
32000
CY2023Q1 tovx Long Term Debt Maturity Year Six
LongTermDebtMaturityYearSix
9000
CY2023Q1 tovx Long Term Debt.
LongTermDebt.
226000
CY2023Q1 tovx Number Of Operating Lease For Facilities
NumberOfOperatingLeaseForFacilities
2
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2023Q1 tovx Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
CY2023Q1 tovx Percentage Of Office Leases Owned By Subsidiary
PercentageOfOfficeLeasesOwnedBySubsidiary
1
CY2023Q1 tovx Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
144000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
107000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
490000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
663000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
673000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
589000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
368000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2783000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
544000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2239000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
437000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1802000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001410578-23-000987-index-headers.html Edgar Link pending
0001410578-23-000987-index.html Edgar Link pending
0001410578-23-000987.txt Edgar Link pending
0001410578-23-000987-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230331.xsd Edgar Link pending
tmb-20230331x10q.htm Edgar Link pending
tmb-20230331x10q001.jpg Edgar Link pending
tmb-20230331xex10d1.htm Edgar Link pending
tmb-20230331xex10d2.htm Edgar Link pending
tmb-20230331xex31d1.htm Edgar Link pending
tmb-20230331xex32d1.htm Edgar Link pending
tmb-20230331_cal.xml Edgar Link unprocessable
tmb-20230331_def.xml Edgar Link unprocessable
tmb-20230331_lab.xml Edgar Link unprocessable
tmb-20230331_pre.xml Edgar Link unprocessable
tmb-20230331x10q_htm.xml Edgar Link completed